

James A. FitzPatrick
Nuclear Power Plant
P.O. Box 41
Lycoming, New York 13093
315 342.3840



**New York Power
Authority**

Harry F. Salmon, Jr.
Site Executive Officer

December 14, 1995
JAFP-95-0549

U.S. Nuclear Regulatory Commission
Attn: Document Control Desk
Mail Station P1-137
Washington D.C. 20555

**Subject: James A. FitzPatrick Nuclear Power Plant (JAFNPP)
Docket No. 50-333
10 CFR 26, Appendix A, "Guidelines For Drug And Alcohol
Testing Programs"**

Gentlemen:

This report is provided to you in accordance with 10 CFR 26, Appendix A, Section 2.8, "Quality Assurance and Quality Control" requirements.

On November 15, 1995, the Fitness For Duty Administrator at JAFNPP identified a urine blind test specimen (BTS) test result that had been incorrectly reported (positive opiate BTS reported as negative) by the facilities Department of Health and Human Services (H.H.S) testing laboratory. Due to the presence of an interfering agent found in the BTS during sample analysis, and because of the laboratory's reporting standards and regulations, the urine BTS was reported as negative. The Power Authority initiated an investigation to identify the origin of the contamination. However, neither the source nor the reason for the existence of the interfering agent could be determined.

The subject test specimen Number T46414 was prepared by Forensic Control Company. Forensic Control Company laboratory prepared the test specimen for Bensinger, DuPont and Associates (BDA), the company contracted by JAFNPP to supply BTS samples.

TEST SPECIMEN NUMBER T46414 SAMPLE COMPOSITION AS PREPARED BY
FORENSIC CONTROL COMPANY:

Matrix - Human urine
Identity and Concentration of Opiates -
Methamphetamines - 1600ng/ml
Amphetamines - 310ng/ml

9512190444 951214
PDR ADCK 05000333
P PDR

A022
11

United States Nuclear Regulatory Commission

Document Control Desk

Subject: Docket No. 50-333

10 CFR 26, Appendix A, "Guidelines For Drug And Alcohol Testing Programs"

PAGE -2-

The Specimen Lot was confirmed using gas chromatography/mass spectrometry (GC/MS) technique at three H.H.S. certified laboratories prior to its being placed in service on September 9, 1995. Laboratories confirmed their specimens within $\pm 20\%$ of the target levels with no indications of interfering agents within the test specimen.

Specimen Number T46414 was entered into normal specimen shipment by JAFNPP and received by MetPath Incorporated, the JAFNPP H.H.S. testing laboratory, on November 3, 1995. On November 3, 1995, Specimen Number T46414 was screened positive for Amphetamines by Enzyme Multiplied Immunoassay Technique (EMIT) testing. A confirmation test by GC/MS was performed on November 4, 1995 with results indicating the presence of Amphetamine at a concentration of 311 ng/ml and Methamphetamine at a concentration of 1554 ng/ml. However, due to the presence of an interfering substance with qualifying ions, the specimen could not be reported positive. On November 7, 1995, MetPath Incorporated repeated a GC/MS analysis of the test specimen, with the same positive concentration results. The interfering agent was still present and could not be eliminated. Laboratory criteria could not be met, and due to procedural guidelines, MetPath Incorporated was required to report test results for Test Specimen T46414 as negative.

IMMEDIATE CORRECTIVE ACTIONS:

Administrative officials at both Forensic Control Company and MetPath Incorporated reported that investigations were unsuccessful in identifying the source of the interfering substance. BDA informed JAFNPP that no interference had been reported by other BDA clients who had been provided specimens from this same lot.

BDA officials stated that the criteria for laboratory confirmation are stringent, and that the reporting of false negatives will occur in the strict criteria required to prevent the reporting of false positives. In their opinion, the issue with false negatives is not that they will occur, but their frequency. The JAFNPP false negative rate of 1995 is 3.3 per cent, which, in the judgement of Bensinger, DuPont and Associates, is not a problem.

United States Nuclear Regulatory Commission

Document Control Desk

Subject: Docket No. 50-333


10 CFR 26, Appendix A, "Guidelines For Drug And Alcohol
Testing Programs"

PAGE -3-

We concur with the opinion of BDA that the low percentage rate of reported false negatives at JAFNPP does not constitute an immediate cause for concern. However, what does concern the Authority is the failure by both the BTS supplier and H.H.S. laboratory to provide a quality explanation as to the reason for the presence of the interfering agent in the BTS. As a result, the Power Authority will establish new contracts with both an alternate BTS supplier and H.H.S. testing laboratory.

If you have questions concerning this issue, please contact Mr. Gordon Brownell of my staff at (315) 349-6360.

Very truly yours,



HARRY P. SALMON, JR.

HPS:GJB:las

Attachments (1)

cc: USNRC, Region I
USNRC Resident Inspector
USNRC Project Directorate

659035326
 3153496412
 659035326
 BR
 NY POWER AUTHORITY
 DR. J. HEITZMAN, MRO
 961 CANAL STREET
 SYRACUSE NY 13210
 11/03/95
 11/06/95 0086
 11/10/95
 31752
 T46414 1015

CLIENT INFO:

8082425

TEST NAME ABNORMAL RESULT NORMAL UNITS REFERENCE RANGE

(01)

DRUG SCREEN					
AMPHETAMINE		NEGATIVE			
COCAINE		NEGATIVE			
OPIATES		NEGATIVE			
MARIJUANA		NEGATIVE			
PHENCYCLIDINE		NEGATIVE			

THE CHAIN OF CUSTODY PROCEDURE WAS FOLLOWED ON THIS SAMPLE.

RESULTS CERTIFIED ON: 11/10/95 BY: FAQIR H. AKHTAR

(01) DRUG SCREEN - TEST CUTOFF LEVELS

COMPOUND	SCREENING TEST CUTOFF LEVEL	CONFIRMATORY TEST CUTOFF LEVEL
AMPHETAMINES	1,000	N/A
AMPHETAMINE	N/A	500
METHAMPHETAMINES	N/A	150
COCAINE METABOLITES(S)	300	N/A
OPIATES/METABOLITES	300	N/A
MORPHINE	N/A	300
CODEINE	N/A	15
MARIJUANA METABOLITES	100	15
PHENCYCLIDINE	25	25

UNITS ARE EXPRESSED AS NG/ML (WHICH IS EQUIVALENT TO MCG/L)

Chick
 should be result
 positive 11/15/95
 10 pm
Chick

Reviewed -
 Name *Chick*
 Date 11/15/95

Raymond Samsing M.D.
 Joseph S. O'Brien M.D.
 Paul A. Kaplan M.D.
 Paul A. Kaplan M.D.
 Elizabeth M.D.
 Shear M.D.

11/10/95 11:50 AM